COMPASS PATHW SP.ADR (5Y6) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COMPASS PATHW SP.ADR (5Y6) has a cash flow conversion efficiency ratio of 0.715x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-37.79 Million ≈ $-44.18 Million USD) by net assets (€-52.85 Million ≈ $-61.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of COMPASS PATHW SP.ADR to measure how much of total assets are equity-financed.
COMPASS PATHW SP.ADR - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COMPASS PATHW SP.ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore COMPASS PATHW SP.ADR (5Y6) investment intensity to see how much of total assets are deployed in long-term investments.
COMPASS PATHW SP.ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COMPASS PATHW SP.ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
J Resources Asia Pasifik Tbk
JK:PSAB
|
0.077x |
|
Kempower Oyj
HE:KEMPOWR
|
0.030x |
|
VGI Public Company Limited
BK:VGI
|
0.002x |
|
AGF Management Limited
F:A3J
|
-0.021x |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
0.111x |
|
Shinyoung HappyTomorrow No.5 Special Purpose Acquisition Company
KQ:323280
|
-0.079x |
|
Zhejiang Dehong Automotive
SHG:603701
|
-0.014x |
|
Evergent Investments SA
RO:EVER
|
0.017x |
Annual Cash Flow Conversion Efficiency for COMPASS PATHW SP.ADR (2021–2025)
The table below shows the annual cash flow conversion efficiency of COMPASS PATHW SP.ADR from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see COMPASS PATHW SP.ADR (5Y6) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-52.85 Million ≈ $-61.78 Million |
€-157.24 Million ≈ $-183.83 Million |
2.975x | +486.18% |
| 2024-12-31 | €154.69 Million ≈ $180.85 Million |
€-119.19 Million ≈ $-139.34 Million |
-0.770x | -78.61% |
| 2023-12-31 | €225.74 Million ≈ $263.92 Million |
€-97.38 Million ≈ $-113.84 Million |
-0.431x | +25.85% |
| 2022-12-31 | €181.28 Million ≈ $211.94 Million |
€-105.45 Million ≈ $-123.28 Million |
-0.582x | -144.21% |
| 2021-12-31 | €284.41 Million ≈ $332.51 Million |
€-67.75 Million ≈ $-79.20 Million |
-0.238x | -- |
About COMPASS PATHW SP.ADR
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as … Read more